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The recent discovery of thousands of long non-coding (lnc)RNAs in the human genome
has prompted investigation of the potential roles of these molecules in human biology
and medicine. Indeed, it is now well documented that many lncRNAs are involved in key
biological processes, including dosage compensation, genomic imprinting, chromatin reg-
ulation, alternative splicing of pre-mRNA, nuclear organization; and potentially many other
biological processes, which are yet to be elucidated. Recently, a number of studies have
also reported that lncRNAs are dysregulated in a number of human diseases, including sev-
eral cancers and neurological disorders. Although many of these studies have fallen short
of implicating lncRNAs as causative, they suggest potential roles that warrant further in
depth investigations. In this review, we discuss the current state of knowledge regarding
the roles of lncRNAs in cancer and neurological disorders, and suggest potential future
directions in this rapidly emerging ﬁeld.
Keywords: long non-coding RNAs, large non-coding RNAs, lincRNAs, cancer, neurological disorders, neurodegen-
eration, human disease
INTRODUCTION
A number of studies over the past decade have now shown that
mammalian genomes encode thousands of long non-codingRNAs
(lncRNAs), which are mRNA-like transcripts that lack protein-
coding capacity. It is now estimated that the human and mouse
genomes produce almost as many lncRNAs as mRNAs (Carninci
et al., 2005;Mattick andMakunin,2006;Carninci andHayashizaki,
2007;He et al., 2008; Guttman et al., 2009; Khalil et al., 2009; Cabili
et al., 2011). More importantly, recent studies have demonstrated
that lncRNAs are involved in key biological processes including
dosage compensation, genomic imprinting, chromatin regulation,
alternative splicing of pre-mRNA and nuclear organization. Fur-
thermore, some lncRNAs have been shown to regulate the expres-
sion of hundreds of protein-coding genes by various mechanisms
(Khalil et al., 2009; Gupta et al., 2010; Tsai et al., 2010; Guttman
et al., 2011; Nagano and Fraser, 2011). For example, the lncRNA
Xist, which is required for X chromosome inactivation (Xi) in
mammalian females (Brockdorff et al., 1992; Brown et al., 1992),
represses hundreds of genes during Xi by recruiting and tethering
repressive chromatin-modifying complexes to the inactive X chro-
mosome (Zhao et al., 2008; Jeon and Lee, 2011). Perhaps equally
interesting is the tangled web of several lncRNAs that are also
involved in this process by regulating the expression and action of
Xist (Lee et al., 1999; Ogawa and Lee, 2003).
Another lncRNA, termed HOTAIR, was shown to regulate the
expression of hundreds of genes genome-wide in trans (Rinn
et al., 2007; Khalil et al., 2009; Gupta et al., 2010; Tsai et al.,
2010).HOTAIR functions bybinding toboth thepolycomb repres-
sive complex 2 (PRC2) and the histone demethylase LSD1, and
facilitate their co-recruitment to speciﬁc regions of the genome
(Rinn et al., 2007; Khalil et al., 2009; Gupta et al., 2010; Tsai
et al., 2010). Subsequently, PRC2 and LSD1 alter histone modiﬁ-
cations to induce heterochromatin formation and gene repression
(Kouzarides, 2007). Combined, these observations illustrate how a
single lncRNA can regulate the expression of hundreds of protein-
coding genes; and thus, the dysregulation of such a lncRNA could
contribute to the dysregulation of hundreds of genes leading to
abnormal effects on the cell and the organism (Hu et al., 2011;
Wapinski and Chang, 2011). Indeed, a number of recent publica-
tions have reported that lncRNAs are dysregulated in a wide range
of human diseases and disorders. In this review, we will focus on
the potential roles that lncRNAs may play in cancer and neurolog-
ical disorders, as these disorders are the most commonly reported
to be associated with dysregulation of lncRNAs.
POTENTIAL ROLES FOR lncRNAs IN CANCER ETIOLOGY
Cancer is a devastating human disease that remains a challenge
to treat or cure. This is due to the ability of cancerous cells to
proliferate rapidly, resist apoptosis, evade the immune system, and
metastasize to new regions within the body. Despite the identi-
ﬁcation of over 30 tumor suppressor genes and 100 oncogenes
within the human genome, it is yet to be determined how muta-
tions of these genes contribute to the initiation and metastasis of
various cancer types (Hudson, 2011). Recent studies utilizing next
generation sequencing technologies complicated this matter fur-
ther when it was shown that many cancer patients did not harbor
mutations in these protein-coding genes (Hudson, 2011). Intrigu-
ingly, several studies in the past few years have reported that a
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subset of lncRNAs is dysregulated in various cancers (Luo et al.,
2006; Perez et al., 2008; Silva et al., 2010). Furthermore, some of
these lncRNAs are strongly correlated with poor patient progno-
sis and/or metastasis, suggesting a potential role that should be
further investigated. Currently, the detailed functions and mech-
anisms of these lncRNAs are not completely known, however,
they appear to be involved in cellular proliferation and invasive-
ness, which may explain their potential roles in cancer etiology
(Table 1).
Several studies have now shown that the lncRNA HOTAIR is
highly expressed in breast tumors, hepatocellular carcinoma, and
colorectal cancer; and strongly correlates with poor patient prog-
nosis and metastasis (Gupta et al., 2010; Kogo et al., 2011; Yang
et al., 2011b). HOTAIR is expressed from the HOXC gene clus-
ter and negatively regulates the expression of hundreds of genes
genome-wide in trans (Rinn et al., 2007; Khalil et al., 2009; Gupta
et al., 2010; Tsai et al., 2010; Chu et al., 2011). In vitro and in vivo
studies suggest thatHOTAIR is involved inmetastasis by unknown
mechanisms (Gupta et al., 2010). However, since HOTAIR is
known to interact with several chromatin-modifying complexes,
one can envision that the upregulation of HOTAIR, which is
observed in several cancers, causes changes in the epigenomic land-
scape of cancer cells resulting in altered gene expression programs
that promote an invasive phenotype (Figure 1A; Rinn et al., 2007;
Khalil et al., 2009; Gupta et al., 2010; Tsai et al., 2010). Indeed,
in vitro studies have shown that over-expression of HOTAIR in
cell lines leads to the recruitment of the repressive complex PRC2
to over 800 additional loci genome-wide including tumor sup-
pressor genes (Gupta et al., 2010). HOTAIR-mediated repression
of these tumor suppressor genes could be responsible for the
increased proliferation and invasiveness phenotype observed, but
this hypothesis awaits further experimental evidence.
Similar to HOTAIR, the lncRNA ANRIL is also elevated in sev-
eral cancers, and GWAS studies have linked ANRIL with acute
lymphoblastic leukemia, glioma, basal cell carcinoma, nasopha-
ryngeal carcinoma, breast cancer, and plexiform neuroﬁbromas
(Popov and Gil, 2010; Iacobucci et al., 2011; Pasmant et al.,
2011a,b). ANRIL is an antisense lncRNA to several genes involved
in cell cycle regulation: p15/INK4b, p16/INK4a, and p14/ARF
(Pasmant et al., 2007). Studies of ANRIL have provided some
insights into its mechanism of action. It is thought that ANRIL
functions by directing the chromatin-modifying complexes PRC1
and PRC2 to chromatin, since the disruption of ANRIL interac-
tion with PRC1 or knockdown of ANRIL abolishes the repression
of INK4b/ARF/INK4a locus, which is a known target of PRC1
and PRC2 (Yap et al., 2010; Kotake et al., 2011). The elevated
expression of ANRIL in cancer, and consequently the repression
of the INK4b/ARF/INK4a locus, prevents these tumor suppressor
genes from properly regulating the cell cycle. In essence, ANRIL
and HOTAIR operate by similar mechanisms; that is by altering
chromatin structure either locally or over long distances to repress
the expression of tumor suppressor genes. Indeed, it is now well
documented that the epigenomes of cancer cells are distinct from
normal cells (Baylin and Jones, 2011); nevertheless, the molecular
events that lead to these profound changes in cancer epigenomes
are not completely understood. Environmental or genetics fac-
tors that cause lncRNAs to become dysregulated may turn out to
be important players in such events. Further studies are needed
to determine how the expression of lncRNAs, such as HOTAIR
and ANRIL, become initially upregulated in cancer, and whether
the elevated expression is sufﬁcient to cause tumorigenesis and/or
metastasis. Animal models might prove invaluable to get to the
bottom of these key questions.
Recent studies have also identiﬁed lncRNAs that are induced
in response to DNA damage in a p53-dependent manner, includ-
ing linc-P21, PANDA, Tug1, and others (Guttman et al., 2009;
Khalil et al., 2009; Huarte et al., 2010; Hung et al., 2011). Although
these lncRNAs are all activated by p53, their mechanisms of action
appear to be distinct (Figure 1B). For example, linc-P21 represses
hundreds of genes in the p53 pathway by modulating hnRNPK
localization to chromatin (Huarte et al., 2010), while PANDA
interacts with the transcription factor NF-YA to reduce the expres-
sion of pro-apoptotic genes (Hung et al., 2011). Meanwhile, Tug1,
which regulates cell cycle genes, functions via its interaction with
the chromatin-modifying complex PRC2 and Pc2 (Khalil et al.,
2009; Yang et al., 2011a).
The observations that p53 can induce the expression of speciﬁc
lncRNAs are intriguing since they provide new insights into p53-
mediated gene regulation. Although transcriptional activation by
p53 is well studied, its ability to repress transcription remains enig-
matic. The induction of speciﬁc lncRNAs by p53 that leads to gene
repression could be part of the mechanism by which p53 represses
Table 1 | Examples of IncRNAs that are dysregulated in cancer.
IncRNA Disease association Biological function Reference
HOTAIR Breast cancer, hepatocellular carcinoma, and
colorectal cancer
Binds and recruits PRC2 and LSD1 to the
genome to repress gene expression
Gupta et al. (2010), Yang et al.
(2011b), Kogo et al. (2011)
SPRY4-IT1 Melanoma Cell proliferation Khaitan et al. (2011)
MALAT1 Lung adenocarcinoma and hepatocellular carcinoma Alternative splicing of pre-mRNA Ji et al. (2003), Luo et al. (2006)
ncRAN Neuroblastoma Cell proliferation Yu et al. (2009), Zhu et al. (2011)
PRNCR1 Prostate cancer Cell viability Chung et al. (2011)
ANRIL Neural system tumors, cutaneous malignant
melanoma, and other cancers
Silencing of the INK4b–ARF–INK4A tumor
suppressor locus by PRC2 complex recruitment
Pasmant et al. (2007)
Linc-p21 Unknown Induced by p53 upon DNA damage to repress
p53 target genes
Huarte et al. (2010)
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FIGURE 1 | Dysregulation of lncRNAs in cancer cells alters gene
expression by a variety of mechanisms. (A) A subset of lncRNAs (e.g.,
HOTAIR, ANRIL, and others) guide chromatin-modifying complexes such as
PRC2 in cis or in trans to speciﬁc genes to modulate their expression.
However, the upregulation of these lncRNAs, which is observed in several
cancers, leads to non-speciﬁc guidance of chromatin-modifying complexes to
the genome that alters normal gene expression programs. For example, the
non-speciﬁc guidance of PRC2 by an upregulated lncRNA in cancer cells to
one or more tumor suppressor genes leads to their repression; and
consequently affects cells ability to regulate their normal proliferation pattern
or induce apoptosis. Conversely, an upregulated lncRNA that leads an
activating chromatin-modifying complex to oncogenes may also perturb
normal cellular functions (not shown). (B) A group of lncRNAs is known to be
induced directly by p53, which can be activated by various stimuli including
DNA damage.These lncRNAs, once activated, modulate gene expression by a
variety of mechanisms via their protein partners.
its target genes. Thus, mutations in p53 that hinder its ability to
activate these lncRNAs, or mutations in the p53 binding site in
the promoter of one or more of these lncRNAs may contribute to
cancer as they may cause p53 to lose its ability to repress down-
stream target genes. Ongoing whole genome sequencing of cancer
genomes may uncover potential mutations in the promoters of
lncRNAs that prevent p53 binding. Also, an in depth understand-
ingof p53 induced lncRNAsmayprovidenovel insights into cancer
initiation and/or progression.
In addition to regulation of gene expression by lncRNAs at
the transcriptional level, other lncRNAs regulate gene expres-
sion post-transcriptionally. Such lncRNAs,when dysregulated, can
also lead to undesired biological consequences. For example, the
lncRNA MALAT1 (Metastasis Associated Lung Adenocarcinoma
Transcript 1), which is associated with high incidence of metas-
tasis in lung tumors and poor patient prognosis (Ji et al., 2003),
regulates alternative splicing of pre-mRNAs by modulating the
phosphorylation of SR proteins (Tripathi et al., 2010). However, at
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this stage we can only speculate that the dysregulation of MALAT1
and consequently the altered ratios of alternative splicing products
may contribute to cancer, for example, by increasing the pro-
duction of protein isoforms that promote cell proliferation and
invasiveness. This hypothesis is supported by studies that have
reported altered ratios of spliced mRNAs in cancer cells and tissues
(David and Manley, 2010).
The lncRNAs SPRY4-IT1, ncRAN, and PRNCR1 and others
have also been shown to be dysregulated in various cancers; how-
ever, the mechanisms of these lncRNAs are not currently known
(Table 1;Yu et al., 2009; Chung et al., 2011; Khaitan et al., 2011). By
in vitro studies, all of the three aforementioned lncRNAs appear
to affect cell viability or proliferation (Yu et al., 2009; Chung et al.,
2011; Khaitan et al., 2011; Zhu et al., 2011). Importantly, deple-
tion of the lncRNA ncRAN makes cancer cells more susceptible
to treatments with chemotherapeutic agents in vitro (Zhu et al.,
2011). Uncovering the molecular mechanisms of these lncRNAs
will be invaluable in understanding why cancer cells become more
susceptible to chemotherapy when a speciﬁc lncRNA levels are
reduced. Also, future studies to validate these observations in vivo
will be critical as in vitro studies have many caveats, and may not
always reﬂect actual physiological conditions. Nevertheless, these
observations, although preliminary, are potentially exciting since
they suggest that combined chemotherapy and siRNAs against
speciﬁc lncRNAs may prove to be a powerful approach in treat-
ing resistant tumors. Currently, the technology to target lncRNAs
in vivo still requires years of research in animal models ﬁrst, and
then in clinical trials. If successful, such technology may provide
new therapeutic strategies that increase the percentage of effective
cancer treatments.
In summary, lncRNAs may prove to be potential drug targets
for cancer therapies. These potential treatments can be combined
with conventional methods to treat difﬁcult cases or tumors that
are highly resistant to conventional methods alone. Finally, eluci-
dating the exact functions and mechanisms of lncRNAs that are
dysregulated in cancer may provide fundamental new insights into
cancer biology in general.
POTENTIAL ROLES FOR lncRNAs IN NEUROLOGICAL
DISORDERS
Environmental and/or genetic factors can give rise to many types
of neurological disorders that result in irregular brain function.
Several mechanisms by which such factors lead to neurologi-
cal disorders have been proposed including protein aggregation,
oxidative stress, improper inﬂammatory response, and increased
apoptosis (Double et al., 2010). A hallmark of neurological dis-
orders is that they affect speciﬁc regions within the brain, while
other regions remain functional (Double et al., 2010). Currently,
a full understanding of neurological disorders and adequate ther-
apies are both lacking. Previously, it was shown that hundreds of
lncRNAs show speciﬁc localization to neuroanatomical regions,
cell types, or subcellular compartments within the brain (Mercer
et al., 2008) suggesting that a subset of these lncRNAs could con-
tribute to neurological disorders when they become dysregulated.
In this section, we highlight several studies that have reported dys-
regulation of lncRNAs in neurological disorders (Table 2), and
attempt to provide some insights into their potential mechanisms
of action.
DYSREGULATION OF lncRNAs IN TRINUCLEOTIDE REPEAT
NEUROLOGICAL DISORDERS
Trinucleotide repeat disorders are a set of genetic disorders caused
by the expansion of speciﬁc trinucleotide sequences (e.g., CAG,
CGG, etc.) above a certain threshold leading to defects in the
expression or functions of speciﬁc genes. Such disorders include
fragile X syndrome (FXS), fragile X tremor ataxia syndrome
(FXTAS), Huntington’s disease, spinocerebellar ataxias, and oth-
ers. In addition to protein-coding genes, the expression, and/or
function of several lncRNAs have been shown to be affected by
trinucleotide repeats raising the possibility that these lncRNAs
may also contribute to the disease phenotype.
Previously, both Khalil et al. (2008) and Ladd et al. (2007)
reported the discovery of two lncRNAs, FMR4, and ASFMR1 that
are expressed from the fragile X mental retardation 1 gene (FMR1)
locus; which is associatedwith FXS, FXTAS, and potentially autism
(Penagarikano et al., 2007; Gallagher and Hallahan, 2011; Sokol
et al., 2011). FXS is an X-linked neurological disorder and the
leading cause of inherited mental retardation; and FXTAS is a late
onset neurodegenerative disorder (Gallagher and Hallahan, 2011).
Both disorders result from CGG trinucleotide repeat expansion in
the 5′ UTR of FMR1 (Verkerk et al., 1991; Oostra and Willemsen,
2003; Godler et al., 2010; Gallagher and Hallahan, 2011). Subse-
quent studies to the discovery of the CGG expansion in the FMR1
locus demonstrated that there is high variability in the phenotype
of FXS and FXTAS patients that could not be simply explained
by FMR1 levels alone (Tassone et al., 2001; Gallagher and Hal-
lahan, 2011). Thus, raising the possibility that dysregulation of
FMR4 and ASFMR1 could be contributing to the variability in
phenotype observed in these patients.
Both FMR4 and ASFMR1, similar to FMR1, are upregulated in
FXTAS and are repressed in FXS patients (Ladd et al., 2007; Khalil
et al., 2008). However, the underlying molecular mechanisms of
FMR4 and ASFMR1 are yet to be determined. In vitro studies of
FMR4 have shown that it has an anti-apoptotic function in human
Table 2 | Examples of IncRNAs that are dysregulated in neurological disorders.
IncRNA Disease association Biological function Reference
FMR4 Fragile X syndrome/FXTAS Anti-apoptotic Khalil et al. (2008)
ASFMR1 Fragile X syndrome/FXTAS Unknown Ladd et al. (2007)
ATXN8OS Spinocerebellar ataxia type 8 Unknown Moseley et al. (2006)
BC200 Alzheimer’s disease Translational control Mus et al. (2007)
BACE1-AS Alzheimer’s disease Concordantly regulates BACE1 expression Faghihi et al. (2008)
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cells (Khalil et al., 2008). It is possible that FMR4 anti-apoptotic
function protects neurons or their progenitors during develop-
ment from apoptosis. This is consistent with a recent discovery
from Harvey Lodish’s laboratory that the lncRNA ESlncRNA,
which also has an anti-apoptotic function, protects progenitors
of red blood cells from apoptosis (Hu et al., 2011). However, since
FMR4 is only conserved in primates, it is difﬁcult to assess its
function in animal models such as mouse or Drosophila. One
intriguing possibility is that FMR1, FMR4, and ASFMR1 work
cooperatively in a RNA–protein network, and disruption of these
delicate interactions may lead to undesired effects on brain func-
tion. Indeed, this may explain the wide range of variability in
phenotype observed in FXS and FXTAS, as the magnitude of devi-
ation from the physiological levels of FMR4 and/or ASFMR1 can
lead to less or more severe levels of the phenotype (Penagarikano
et al., 2007; Gallagher and Hallahan, 2011).
Long non-coding RNAs have also been reported to be dys-
regulated in spinocerebellar ataxia type 8 (SCA8), which is a
neurodegenerative disease of the cerebellum that affects muscle
and speech coordination (Koob et al., 1999; Mutsuddi et al., 2004).
Within the SCA8 expansion region two genes were identiﬁed:
the protein-coding gene ataxin 8 (ATXN8) with a CAG expan-
sion that encodes a polyglutamine expansion tract protein, and
ataxin 8 opposite strand (ATXN8OS), which is a lncRNA with
a CUG repeat. Transgenic mice expressing both transcripts with
(CTG)116 or with (CTG)11 repeat expansions demonstrated that
the (CTG)116 but not (CTG)11 develop a progressive neuro-
logical phenotype (Moseley et al., 2006). Supporting a role for
the lncRNA in the disease phenotype is a study in Drosophila
where dysregulation of the lncRNA from the SCA8 region leads to
neurodegeneration of the retina (Mutsuddi et al., 2004).
Currently, how a repeat expansion affects the function of a
lncRNA is not completely understood; however, it is known that
aberrant RNAs with a repeat expansion forms secondary struc-
tures that bind and sequester the splicing factor MBNL1 causing
aberrant pre-mRNA splicing (Yuan et al., 2007). Indeed, a study in
mice over-expressing ATXN8OS with the repeat expansion found
that it also becomes associated with MBNL1 in neurons leading to
aberrant splicing of GABT4 (GABA-A transporter 4) and loss of
GABAergic inhibition in the granular cell layer,which is postulated
to contribute to the observed phenotype (Daughters et al., 2009).
Collectively, these studies demonstrate that repeat expansions
not only in protein-coding genes but also in lncRNAs may
contribute to certain human neurological disorders. Some have
referred to this phenomenon as RNA gain of function or RNA
toxicity (Daughters et al., 2009). Studies in FXTAS patients have
also found evidence that FMR1 mRNA with the repeat expansion
remains sequestered in the nucleus, thus explaining the low levels
of FMRP in these patients despite having higher levels of FMR1
mRNA than normal individuals (Tassone et al., 2004; Hagerman
and Hagerman, 2007). It is quite conceivable that other lncRNAs
with either a repeat expansion or mutations that change their
protein-binding capacity could also lead to RNA gain of func-
tion that contributes to other human disorders with unknown
mechanisms. The recent advances in RNA sequencing technolo-
gies may prove to be instrumental in discovering such cases by ﬁrst
identifying mutations in lncRNAs associated with human disease,
and then experimentally testing the effects of such mutations on
the function of lncRNAs.
DYSREGULATION OF lncRNAs IN ALZHEIMER’S DISEASE
Alzheimer’s disease (AD) is a form of dementia that gradually
gets worse over time, affecting memory, cognition, and behavior
(Goedert and Spillantini, 2006; Ballard et al., 2011). A common
characteristic of AD is the formation of protein aggregates in neu-
rons (Sokol et al., 2011). These aggregates, called amyloid plaques,
are formed from the shift in processing of the amyloid-β precursor
protein, APP, by the α-, β-, and γ-secretases (Minati et al., 2009;
Ballard et al., 2011). This shift results in increased levels of the
amyloid-β protein product, Aβ 1–42, which is the primary protein
of the aggregates (Minati et al., 2009; Ballard et al., 2011). Nor-
mally, there is a balance between levels of Aβ 1–42 and Aβ 1–40
products, but this balance is disrupted in AD by unknown mech-
anisms, and is thought to cause amyloid plaques (Minati et al.,
2009; Ballard et al., 2011). It is believed that the presence of these
plaques is responsible for the atrophy and inﬂammation observed
in the brains of Alzheimer’s patients. However, this conclusion has
been debated (Sokol et al., 2011).
A number of studies have now shown that the expression of
several lncRNAs is altered in AD patients. The primate-speciﬁc
lncRNA BC200, which is expressed almost exclusively in neuronal
cells and plays a role in regulating the translation of speciﬁc pro-
teins, is dysregulated inAD (Tiedge et al., 1993;Muddashetty et al.,
2002). Although the expression of BC200 steadily declines in the
brain under normal aging conditions, it becomes upregulated in
AD patients, and the severity of AD correlates with levels of BC200
(Mus et al., 2007). Functionally, BC200 has been implicated in
regulating the translation of speciﬁc proteins in somatodendritic
domains of neurons, and thus its upregulation in AD patients
may lead to changes in protein production that are responsible,
directly or indirectly, for plaque formation. Studies of BC1, the
mouse functional homolog of BC200,have shown that BC1knock-
out mice exhibit behavioral changes, demonstrating an important
role for BC1 in brain function (Lewejohann et al., 2004). A deeper
understanding of BC200 and BC1 regulation may provide new
insights into AD pathogenesis.
The lncRNA BACE1-AS, which is transcribed antisense to
the protein-coding gene BACE1, is also highly expressed in AD
patients (Faghihi et al., 2008). BACE1 is a β-secretase that is
responsible for APP cleavage into Aβ, and is the major Aβ produc-
ing β-secretase in the brain (Vassar et al., 2009). BACE1 expression
is regulated post-transcriptionally by BACE1-AS both in vitro and
in vivo (Faghihi et al., 2008). Importantly, levels of both the Aβ
1–40 and Aβ 1–42 become reduced upon BACE1-AS knockdown,
without affecting APP levels (Faghihi et al., 2008). This suggests
that BACE1-AS may regulate the levels of pathogenic Aβ by a
shift in the processing ability of APP by BACE1. Collectively, these
ﬁndings suggest that at least under some conditions, BACE1-AS
upregulation may be responsible for the elevated levels of BACE1
seen in AD patients, and indicate a mechanism in which BACE1-
AS upregulation serves to alter APP processing toward Aβ 1–42
(Faghihi et al., 2008). Further studies are needed to determine at
which stage of AD the upregulation of BACE1-AS occurs, and if it
is sufﬁcient for AD pathogenesis.
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POTENTIAL MECHANISMS OF lncRNAs AND IMPLICATIONS
FOR HUMAN DISEASE
Although the full range of mechanisms of lncRNAs is yet to be elu-
cidated, a number of studies have now provided some insights into
thesemechanisms.Herewewill only highlight knownmechanisms
of lncRNAs as a full discussion of this topic has been published
recently (Wang and Chang, 2011).
lncRNAs AS CELLULAR “NAVIGATION SYSTEMS”
For the past few years, much attention has been focused on the
role of lncRNAs in regulating gene expression via their inter-
actions with chromatin-modifying complexes. Previously, two
genome-wide studies using RNA co-immunoprecipitation assays
found numerous nuclear lncRNAs to be physically associated
with chromatin-modifying complexes including PRC2, CoREST,
SMCX,and others,which are responsible for regulating the expres-
sion of hundreds of genes (Khalil et al., 2009; Zhao et al., 2010).
Moreover, these lncRNAs regulate similar genes to their protein-
binding partners by unknown mechanisms (Khalil et al., 2009;
Zhao et al., 2010; Guttman et al., 2011). Subsequent studies indi-
cated that some of these lncRNAs may function by directing
chromatin-modifying complexes to their genomic targets (Gupta
et al., 2010; Tsai et al., 2010). In essence, some lncRNAs may turn
out to be cellular “navigation systems” for proteins lacking direct
DNA binding capacity.
The widespread interactions between lncRNAs and chromatin-
modifying complexes suggest that disruption of these interactions
could have profound effects on gene expression by misdirect-
ing chromatin-modifying complexes to the genome. For exam-
ple, a dysregulated lncRNA that directs a repressive chromatin-
modifying complex inappropriately to a tumor suppressor gene,
or away from an oncogene, may result in a similar outcome as a
mutation in either one of these types of genes. Further studies are
needed to uncover how lncRNAs recognize their protein-binding
partners while excluding the thousands of other proteins in the
cell. These studies may lead to the development of bioinformatic
tools that can be used to predict lncRNA structures, and how some
mutations in lncRNAs may lead to inappropriate lncRNA–protein
interactions (Khalil and Rinn, 2011). Unfortunately, prediction of
secondary structures of lncRNAs is an area that is still in its infancy,
and may require tremendous efforts of research and innovation.
lncRNAs AS MOLECULAR SCAFFOLDS
Some lncRNAs have been shown to play structural roles that are
critical for organizing speciﬁc compartments within the cell. It has
been known for over 20 years that Xist is required for the forma-
tion of the Barr body, which appears as a condensed chromatin
usually at the periphery of nuclei (Brown et al., 1992; Chadwick
and Willard, 2003). The lncRNAs MALAT1 and NEAT1 serve as
molecular scaffolds for proteins in nuclear speckles and paraspeck-
les, respectively. Recently, HOTAIR was shown to also serve as
a molecular scaffold for PRC2 and LSD1 at endogenous target
genes (Tsai et al., 2010). It is very likely that many other lncR-
NAs serve as scaffolds similar to the lncRNAs mentioned above, as
numerous lncRNAs are known to bindmultiple protein complexes
(Pandey et al., 2008; Khalil et al., 2009; Gupta et al., 2010; Tsai et al.,
2010; Guttman et al., 2011). Nonetheless, lncRNAs recognition of
their protein partners is a missing link in our understanding of
this mechanism of action. Finally, mutations in lncRNAs, which
function as molecular scaffolds for proteins, may result in disease
state by altering the localization of proteins, or by altering the
composition of nuclear and/or cytoplasmic compartments.
lncRNA AS miRNA “SPONGES”
Recently, lncRNAs have been implicated in regulating gene expres-
sion post-transcriptionally by binding to microRNAs (miRNAs)
and preventing them from regulating their mRNA targets (Cesana
et al., 2011). This ﬁnding is intriguing since it adds a new layer
to post-transcriptional gene regulation by involving two distinct
classes of non-coding RNAs. However, a number of key questions
regarding this mechanism of action are yet to be elucidated. (1)
What are the factors/proteins that regulate lncRNA interactions
with miRNAs? (2) Do lncRNAs, which bind to miRNAs, become
targeted for deadenylation and consequently degradation similar
to mRNAs? (3) What are the dynamics of lncRNAs interactions
with miRNAs? These key questions and others must be addressed
to understand this novel mechanism of post-transcriptional gene
regulation.
MicroRNAs have been previously implicated in a wide range of
human diseases including cancer and neurological disorders (Bar-
tel, 2004;Mattick andMakunin, 2005;Cho, 2007; Ikeda et al., 2007;
Huang et al., 2008; Rosenfeld et al., 2008). However, the mecha-
nisms by which miRNAs contribute to many of these diseases are
not completely known. With a subset of lncRNAs potentially reg-
ulating the interactions of miRNAs to mRNAs, it is conceivable
that dysregulation of such lncRNAs can lead to dramatic changes
in mRNAs and/or protein levels reminiscent of disease state.
In summary, lncRNAs utilize various mechanisms (e.g., guid-
ance of proteins to speciﬁc genomic loci, structural roles, and as
molecular decoys, etc.) to carry out their cellular functions. In each
case we have yet to fully elucidate the entire mechanism of action,
nonetheless, we are beginning to get glimpses into the mysterious
world of lncRNAs.
CONCLUDING REMARKS
It is now evident that lncRNAs play important roles in many key
biological processes, although their mechanisms of action are yet
to be fully elucidated. The abundance of information that remains
to be learned about these fascinating macromolecules is vast, yet
some key trends have emerged. In light of the importance of
lncRNAs in regulating gene expression, it is not surprising that
dysregulation of lncRNAs have been observed in disease states.
While this review focused on the potential roles of lncRNAs in
cancer and neurological disorders, it is likely that dysregulation of
lncRNAs contributes to many other human diseases and disorders.
Finally,many studies have focused simply on discovering lncRNAs
that are dysregulated in human disease. However, the ﬁeld must
move toward functional and mechanistic studies of lncRNAs to
fully appreciate the role of these novelmolecules in human biology
and medicine.
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